Description: (-)-Indolactam V (ILV) is a protein kinase C activator, which strongly directs human ES cell-derived definitive endoderm into pancreatic endoderm.
In Vitro: Pancreatic endoderm induction by ILV alone has been shown to generate approximately 53% PDX1-positive cells, in contrast to 25% PDX1-positive cells achievable with standard inductors, FGF10, RA and CYC. Here, using human iPS-derived definitive endoderm, we demonstrated robust induction of pancreatic endoderm markers, PDX1, NGN3 and NEUROD1, only after inclusion of ILV to the FGF10, RA and CYC cocktail, underscoring the feasibility of generating pancreatic endoderm cells from human iPS cells through ILV-mediated guidance. It has been proposed that ILV may share an RA-dependent signaling pathway, allowing ultimately to streamline the process of efficient pancreatic endoderm derivation.  Due to the structural relatedness of the lyngbyatoxins and teleocidin, ILV was predicted to be a biosynthetic intermediate and was confirmed via in vitro prenylation by LtxC. The levels of ILV present in the heterologous host suggest an inefficient prenylation reaction with only 10% of ILV being converted to LTX. (-)-Indolactam V induces differentiation of a substantial number of Pdx1-expressing cells from human ESCs. (-)-Indolactam V works specifically at one stage of pancreatic development, inducing pancreatic progenitors from definitive endoderm. (-)-Indolactam V (ILV), when combined with growth factors, can direct the differentiation of hESCs such that >45% of the cells become Pdx1-expressing pancreatic progenitors. 
4. Glover KP, et al. Synergistic Gene Expression Signature Observed in TK6 Cells upon Co-Exposure to UVC-Irradiation and Protein Kinase C-Activating Tumor Promoters. PLoS One. 2015 Oct 2;10(10):e0139850.
|Solubility||10 mM in DMSO|
|Contents||1 vial supplied at requested quantity.|